Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: A randomized clinical trial

Nephrology Dialysis Transplantation

Volumn 28, Issue 11, 2013, Pages 2823-2833

  Esteghamati, Alireza ^a   Noshad, Sina ^a   Jarrah, Sorour ^b   Mousavizadeh, Mostafa ^a   Khoee, Seyed Hamid ^b   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood pressure control; Diabetic nephropathy; Glomerular filtration rate; Mineralocorticoid receptor antagonist; Urinary albumin excretion

Indexed keywords

ALBUMIN; ENALAPRIL; LOSARTAN; POTASSIUM; SPIRONOLACTONE;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

BLOOD PRESSURE CONTROL; DIABETIC NEPHROPATHY; GLOMERULAR FILTRATION RATE; MINERALOCORTICOID RECEPTOR ANTAGONIST; URINARY ALBUMIN EXCRETION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; PROTEINURIA; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 84890086278     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft281     Document Type: Article

References (44)

1. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002; 25: 476-481
2. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999; 159: 1873-1880
3. Javanbakht M, Baradaran HR, Mashayekhi A et al. Cost-ofillness analysis of type 2 diabetes mellitus in Iran. PLoS One 2011; 6: e26864
4. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes. Diabetes 2006; 55: 1832-1839
5. American Diabetes Association. Standards of medical care in diabetes- 2012. Diabetes Care 2012; 35 (Suppl 1): S11-S63
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
7. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49: 12-26
8. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354: 359-364
9. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet 2008; 372: 547-553
10. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132-1140
11. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836
12. Bertocchio JP,Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011; 79: 1051-1060
13. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123
14. Nielsen SE, Persson F, Frandsen E et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012; 29: e184-e190
15. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl 1): S64-S71
17. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
18. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926
19. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49
20. Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211
21. Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650
22. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542
23. van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292
24. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
25. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51
26. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30: 418-424
27. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
28. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
29. Wrenger E, Muller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147-149
30. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
31. Chrysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
32. Yoneda T, Takeda Y, Usukura M et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-1333
33. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
34. Zhou X, Ono H, Ono Y et al. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004; 24: 242-249
35. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008; 12: 233-242
36. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364
37. Leopold JA, Dam A, Maron BA et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-197
38. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009; 308: 53-62
39. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010; 12: 252-257
40. Ninomiya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821
41. Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64
42. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
43. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-S155
44. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin- converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600